Pharmaceutical

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Peritoneal Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Peritoneal Cancer.

Apr 19, 2024 - 00:00
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Peritoneal Cancer.
Read the original article

Tags:

Previous Article

Solving antibiotic and pesticide resistance with infectious worms

Next Article

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Solid Tumor: Likelihood ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Misdiagnoses cost the U.S. 800,000 deaths and serious disabilities every year, study finds

Misdiagnoses cost the U.S. 800,000 deaths and serious d...

Jul 22, 2023

New definition of a human embryo proposed amid rapid scientific advances

New definition of a human embryo proposed amid rapid sc...

Aug 17, 2023

STAT+: Pharmalittle: We’re reading about drug price hikes, Bayer strategic moves, and more

STAT+: Pharmalittle: We’re reading about drug price hik...

Jan 18, 2024